# Capecitabine as Second-Line Therapy in Treating Patients With Stage IV Pancreatic Cancer Who Have the Thymidylate Synthase Gene

> **NCT00303927** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 65 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** capecitabine

## Key facts

- **NCT ID:** NCT00303927
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2007-09
- **Final completion:** —
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2010-03-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00303927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00303927, "Capecitabine as Second-Line Therapy in Treating Patients With Stage IV Pancreatic Cancer Who Have the Thymidylate Synthase Gene". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00303927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*